A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibodyChad J. Swanson, Jeffrey L. Cummings, Yong Zhang et al.|Alzheimer s Research & Therapy|2021Cited by 818
Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme inductionMarc Labelle, Robert N. Young, S. Grossman et al.|Bioorganic & Medicinal Chemistry Letters|1995Cited by 100
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibodyChad J. Swanson, Jeffrey L. Cummings, Yong Zhang et al.|Alzheimer s Research & Therapy|2022Cited by 19